Dyne Therapeutics (NASDAQ:DYN) Stock Rating Upgraded by Wall Street Zen

Dyne Therapeutics (NASDAQ:DYN) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Monday.

Several other analysts have also recently issued reports on the company. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Chardan Capital reissued a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, TD Cowen assumed coverage on Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Price Performance

DYN opened at $23.07 on Monday. The company has a 50-day moving average of $18.70 and a 200-day moving average of $18.19. The company has a market capitalization of $3.81 billion, a P/E ratio of -7.16 and a beta of 1.06. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the business posted ($1.05) earnings per share. Equities analysts expect that Dyne Therapeutics will post -3.02 EPS for the current fiscal year.

Insider Activity

In other news, Director Jason P. Rhodes sold 309,268 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $21.28, for a total transaction of $6,581,223.04. Following the transaction, the director directly owned 1,016,633 shares of the company’s stock, valued at approximately $21,633,950.24. This trade represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 2,334,279 shares valued at $46,221,906. Insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. lifted its position in Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Vanguard Group Inc. raised its holdings in shares of Dyne Therapeutics by 14.9% during the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the period. State Street Corp raised its stake in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after purchasing an additional 1,423,828 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Dyne Therapeutics by 45.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after buying an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at $93,926,000. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.